Quantitative Dynamic Contrast Enhanced Breast MRI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00582764|
Recruitment Status : Completed
First Posted : December 28, 2007
Last Update Posted : July 8, 2015
|Condition or disease||Intervention/treatment|
|Breast Cancer||Other: perform dynamic contrast enhanced (DCE) MRI|
|Study Type :||Observational|
|Actual Enrollment :||116 participants|
|Official Title:||Quantitative Dynamic Contrast Enhanced Breast MRI|
|Study Start Date :||September 2005|
|Actual Primary Completion Date :||July 2015|
|Actual Study Completion Date :||July 2015|
Any patient undergoing MRI guided preoperative needle localization or MRI guided biopsy of the breast.
Other: perform dynamic contrast enhanced (DCE) MRI
With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
- To assess whether the new quantitative MRI method can discriminate between malignant and nonmalignant breast lesions among the lesions seen in conventional MRI. [ Time Frame: December 2008 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00582764
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Sunitha Thakur, PhD||Memorial Sloan Kettering Cancer Center|